Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
TerminatedPhase 2NCT03883386
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine targets histamine, and so may be effective in reducing bone pain.The researchers plan to prospectively assess the effectiveness of loratadine for chronic bone pain in patients with chronic G-CSF use.
Study details
- Official title
- Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use
- Conditions
- Bone Pain
- Interventions
- Drug: Loratadine
- Drug: Placebo
- Sponsor
- University of Michigan
- Start date
- 2019-06-24
- Primary completion
- 2019-10-18
- Sex
- All
- Age range
- from 12 Years to 99 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of neutropenia * Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4 times per month * Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain Inventory (BPI) Exclusion Criteria: * Other sources of chronic pain * Previously tried loratadine for 7 consecutive days or more for bone pain * Allergy to loratadine * Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03883386